ÂÜÀòÂÒÂ×

Huaixiang Hao has an extensive work experience in the field of biomedicine and oncology research. From 2009 to 2012, they worked as a Postdoctoral Fellow at Novartis Institutes for BioMedical Research, followed by a role as a Research Investigator I at Oncology Translational Medicine, Novartis from 2012 to 2014. Huaixiang then joined Novartis Institutes for BioMedical Research again and held various positions, including Research Investigator I, Investigator II, and Investigator III, from 2014 to 2020. Currently, they are the Co-Founder, Executive Director, and Head of Biology at PAQ Therapeutics since June 2023, after previously serving as the Co-Founder, Senior Director, and Head of Biology at the same company from June 2020 to May 2023. In their roles, they have been involved in important research projects, such as addressing patient selection, drug combination, resistance mechanisms, and clinical biomarkers for small molecule inhibitors. Huaixiang has also demonstrated expertise in RAS-MAPK pathway and identified the efficacy of certain inhibitors for specific cancer types. Additionally, they have experience in drafting non-clinical pharmacology sections of documents and mentoring other researchers.

Huaixiang Hao obtained a B.S. in Biological Science from Xiamen University between 1999 and 2003. Following this, they pursued further education at the University of Utah from 2003 to 2009, completing a Ph.D. in Biochemistry.